An individual gene profile provides a window into a person’s medical future, by examining DNA samples, but what are the best ways of regulating this developing technology? LSIPR looks at the challenges and possible solutions.
The technology of genetic screening has come on leaps and bounds since the Human Genome Project finished sequencing the entire human genome, after 13 years’ work, in 2003.
Now direct-to-consumer genetic testing companies can look at sections of your genome to determine risks of developing certain diseases, and deliver the results in a matter of weeks.
California-based 23andMe offers such a service. Describing itself as the largest DNA ancestry service in the world, 23andMe’s personal genome service (PGS) will analyse the DNA it receives from the saliva kit it sends and provide a detailed report about a person’s risks of developing certain diseases.
You need a subscription to continue reading this content.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
News stories up to a week old and feature articles on the day of publication are accessible with a BASIC FREE ACCOUNT.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’; and for basic access to the latest news on the website and weekly email news alerts choose the 'BASIC FREE ACCOUNT' registration.
direct-to-consumer genetic tests, Personal Genome Service, regulation, 23andMe, FDA